Optina’s Retinal Deep Phenotyping platform addresses the major challenges faced by the healthcare system related to an aging population.   Recently, Optina was granted breakthrough device designation by the FDA for our first indication in Alzheimer’s Disease detection which enables a dramatic improvement in the diagnostic accuracy of dementia.   Our ecosystem comprised of a proprietary platform and a network of eye clinics creates a new and efficient means for simple patient stratification. The ecosystem allows for the collection of data rich retinal images with 30X more information than current retinal imaging platforms.   Algorithm development utilizes a ground truth that is based on specifically characterized patients from leading institutions around the world.   With our developing product pipeline, Optina continues to bring clarity and accessibility to early stage diagnosis, improving the life of millions.